ARTV Drops 31% Holding $6.25 a Share in Cash. The Wind-Down Cost Is Still Blank.

October 27, 2026, Eastern Time. Filing accepted 08:30:06 ET; premarket quote 08:54:24 ET; regular-session quote 09:41:03 ET. Cash figures are the company's preliminary, unaudited numbers.

Artiva Biotherapeutics told the market before Tuesday's open that it is stopping AlloNK, its lead program, cutting about 94% of its staff and reviewing "strategic alternatives." The stock fell about a third in premarket trading and was still down about 31% shortly after the open. For a trader, the useful question is narrow: how much cash is behind each share, and how much of it could actually reach shareholders. The filings answer the first part. They do not answer the second.

What the filings say

The 8-K was accepted at 08:30:06 ET on October 27, according to its filing index. It says the board approved the decision on October 22. The attached press release makes five points:

• AlloNK (AB-101) is discontinued, including the planned Phase 3 pivotal trial. B-cell depletion and clinical activity were consistent with earlier data, but longer-term follow-up did not show the durability of response the company says it needed to keep going.
• Two patients died. One Phase 2a participant had fatal leukoencephalopathy after protocol lymphodepletion with cyclophosphamide and fludarabine; the investigator and an independent safety review assessed it as likely fludarabine-associated neurotoxicity. The FDA then asked Artiva to pause enrollment and dosing in that study. A second participant died suddenly about two months after starting treatment; the investigator assessed it as unrelated to AlloNK or any part of the regimen, and the cause has not been determined. The company expressed condolences to the families and plans to publish details of the first case.
• Workforce cut of about 94%, expected to be completed in the first quarter of 2027.
• Strategic review with Leerink Partners as financial advisor. Options named: merger, business combination, sale or licensing of assets, or dissolution and liquidation. The company says there is no assurance of any transaction.
• About $319.1 million in cash, cash equivalents and investments at September 30, 2026, preliminary and unaudited.

The cash per share

The share count comes from the latest 10-Q, filed August 6. Its cover lists 48,890,121 common shares as of July 31. The same report shows 2,170,138 pre-funded warrants from the May offering, exercisable at $0.0001 and already counted as outstanding in basic per-share figures. They belong in the denominator.

Item	Figure
Cash, equivalents and investments, Sept 30 (preliminary)	$319.1 million
Common shares, July 31	48,890,121
Pre-funded warrants, June 30	2,170,138
Share base used here	51,060,259
Cash per share, including pre-funded warrants	about $6.25
Cash per share, common shares only	about $6.53

The 1,097,961 stock options, with a weighted-average exercise price of $6.35, are left out because they are well above today's price. Small changes since July from vesting or employee stock purchases are possible.

Two more reference points from the same filings. Cash was $349.4 million at June 30, so it fell by roughly $30.3 million in the third quarter, before any wind-down costs. And in May the company sold stock at $11.52 a share, raising $300 million gross.

What a wind-down would actually return

Cash per share is not a payout per share. The 8-K says plainly that the company cannot reasonably estimate the total costs of the wind-down. It lists what they will cover: terminating contracts and closing out the clinical trials, leases, other existing liabilities, closing operations and the workforce reduction. It expects most of those costs in the fourth quarter of 2026.

The filings do give a few hard numbers. At June 30, total liabilities were $21.1 million. That included operating lease liabilities of $9.8 million, with $11.1 million of minimum lease payments still due through 2029.

Instead of guessing a liquidation value, we can ask what the price already assumes:

Arithmetic	Figure
Regular-session price, 09:41:03 ET	$4.235
× share base	≈ $216.2 million
Gap to $319.1 million cash	≈ $102.9 million, about 32%
Liabilities at June 30	$21.1 million
Gap not covered by June 30 liabilities	≈ $81.7 million

At the premarket price of $4.13 (08:54:24 ET), the same gap was about $108.2 million.

That last number is not a cost estimate. It is the room the market is leaving for things nobody has quantified yet: severance, contract and trial close-out costs, fourth-quarter spending, how long a process takes, and which path the board picks. A cash distribution is only one of the options. If the board picks a merger instead, shareholders would generally keep a stake in a combined company rather than receive cash, and the terms of that deal would decide what the cash is worth to them.

How the stock traded today

Time (ET)	Price	Change vs prior close	Volume so far
Oct 26 close	$6.16	—	487,078 (full day)
08:54:24, premarket	$4.13	−32.95%	1,221,234
09:41:03, regular session	$4.235	−31.25%	2,337,804

Prices are from the ARTV research page; the prior close is the stored October 26 daily bar. By 09:41 ET the day's volume was already several times a normal full session: daily volume from October 9 to October 26 ranged from about 250,000 to 710,000 shares. These are intraday snapshots, not the close.

One detail matters for the cash math. On October 26, before the announcement, the stock closed at $6.16, about 99% of the $6.25 cash per share calculated above. In other words, the market was already valuing Artiva at roughly its cash before the program was stopped; today's drop took the price to about 68% of it. That is a fact about the price. It says nothing about who knew what. For reference, the stock traded around $10 in late July, and the May offering was priced at $11.52.

What we read into it

FennEdge's interpretation, not a recommendation.

Once a biotech stops its lead program and opens a strategic review, its stock tends to be traded as a claim on its cash rather than on its science. Those claims usually trade below the reported cash figure, because shareholders cannot take the cash out directly: it shrinks while the company winds down, the board decides what happens to it, and a reverse merger can hand much of the company to another business's owners. The discount typically moves when new numbers arrive, such as the quarterly report, a cost estimate, or a proposed deal. That is a description of how such situations have generally been priced, not a forecast for ARTV.

What we don't know

• The audited September 30 cash figure. The 10-Q for the third quarter has not been filed yet.
• The total wind-down cost, including severance and contract terminations. The company says it cannot estimate it.
• Whether the board chooses a merger, an asset sale, a dissolution, or some mix, and on what timeline.
• How much, if anything, a dissolution would return per share, and when. The filings give no figure.

Check it yourself

• SEC filing: 8-K · press release · acceptance record · 10-Q for the June quarter
• ARTV research · October 27 premarket Daily

This article explains common concepts; examples are not trading recommendations.